United Kingdom

People: Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

22 Apr 2019
Change (% chg)

$0.30 (+1.64%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Drejer, Kirsten 

Dr. Kirsten Aarup Drejer has been Independent Vice Chairman of the Board at ZEALAND PHARMA A/S since April 4, 2019. She has been Independent Director of the Company since April 19, 2018. She holds PhD in Pharmacology and a MSc in Pharmacy from the University of Copenhagen. Kirsten Drejer is co-founder and previous CEO of Symphogen A/S (2000-2016) which is a privately biotech company dedicated to the development of mAb mixtures to provide effective treatments to serious diseases including with oncology. Dr. Drejer holds more than 30 years of international experience in the pharmaceutical and biotech industry. Before co-founding Symphogen A/S in 2000, Kirsten Drejer held several scientific and managerial positions at Novo Nordisk A/S, including four years as Director of Diabetes Discovery, and three years as Corporate Facilitator. In addition to her position as member of the board of directors of Symphogen A/S she holds board seats with Bioneer A/S (Chairman), Bioporto A/S, Lyhne & Co, Antag Therapeutics ApS and ResoTher Pharma ApS. Additionally, she is on the Advisory Board for The Faculty of Pharmaceutical Sciences, University of Copenhagen and the Entrepreneurship Advisory Board at Copenhagen Business School.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --